Home / Inspections / 1027562

FDA Inspection 1027562 — Halo Pharmaceutical, Inc. d/b/a Cambrex Whippany

Halo Pharmaceutical, Inc. d/b/a Cambrex Whippany — FEI 2211084

The FDA completed an inspection of Halo Pharmaceutical, Inc. d/b/a Cambrex Whippany on August 24, 2017 in Whippany, NJ. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.

Inspection Details

Classification
No Action Indicated (NAI) (NAI)
End Date
August 24, 2017
Fiscal Year
2017
Product Type
Drugs
Project Area
Drug Quality Assurance
Location
Whippany, NJ (United States)

Facility

Other inspections at this facility

  • 1297650 (NAI Mon Dec 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time))
  • 1197680 (NAI Fri Feb 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time))
  • 1116333 (VAI Fri Dec 20 2019 00:00:00 GMT+0000 (Coordinated Universal Time))
  • 1055544 (VAI Wed May 30 2018 00:00:00 GMT+0000 (Coordinated Universal Time))
  • 1008344 (VAI Mon Mar 20 2017 00:00:00 GMT+0000 (Coordinated Universal Time))

FDA data resources